KZR KEZAR LIFE SCIENCES INC Earnings Reports 8-K Filing 2025 - Financial Results On March 25, 2025, Kezar Life Sciences announced its financial results for the year and quarter ending December 31, 2024, along with topline results from the PORTOLA Phase 2a trial for zetomipzomib in treating autoimmune hepatitis.Get access to all SEC 8-K filings of the KEZAR LIFE SCIENCES INC